JGC
AMLX icon

J. Goldman & Co’s Amylyx Pharmaceuticals AMLX Stock Holding History

J. Goldman & Co’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-135,000
Closed -$2.47M – 338
2023
Q3 		$2.47M Buy
+135,000
New +$2.85M 0.09% 187

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

J. Goldman & Co's AMLX Position: Q3 2025 in Review

J. Goldman & Co sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2025, closing a stake of 258,600 shares — an estimated $1.66M sold.

J. Goldman & Co first reported a position in AMLX in Q4 2022 and held it in 6 quarters. The position peaked at $3.39M in Q3 2023. 169 funds tracked by Wall St. Rank hold AMLX as of Q3 2025.

  • J. Goldman & Co reported no remaining Amylyx Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • J. Goldman & Co sold 258,600 Amylyx Pharmaceuticals shares in Q3 2025, an estimated $1.66M.
  • J. Goldman & Co first reported a position in Amylyx Pharmaceuticals in Q4 2022 and held it in 6 quarters.
  • J. Goldman & Co's Amylyx Pharmaceuticals position peaked at $3.39M in Q3 2023.
  • 169 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2025.

Based on J. Goldman & Co's 13F filing for Q3 2025, filed 14 Nov 2025.